Molecular Partners (MLLC.F) Stock Overview
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MLLC.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 3.60 |
| 52 Week High | CHF 5.35 |
| 52 Week Low | CHF 3.40 |
| Beta | 0.56 |
| 1 Month Change | 2.86% |
| 3 Month Change | n/a |
| 1 Year Change | -28.00% |
| 3 Year Change | -43.84% |
| 5 Year Change | -84.77% |
| Change since IPO | -84.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| MLLC.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | -2.7% |
| 1Y | -28.0% | 17.8% | 11.9% |
Return vs Industry: MLLC.F underperformed the US Biotechs industry which returned 17.8% over the past year.
Return vs Market: MLLC.F underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| MLLC.F volatility | |
|---|---|
| MLLC.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MLLC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MLLC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 153 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease.
Molecular Partners AG Fundamentals Summary
| MLLC.F fundamental statistics | |
|---|---|
| Market cap | US$159.09m |
| Earnings (TTM) | -US$75.81m |
| Revenue (TTM) | n/a |
Is MLLC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLLC.F income statement (TTM) | |
|---|---|
| Revenue | CHF 0 |
| Cost of Revenue | CHF 40.40m |
| Gross Profit | -CHF 40.40m |
| Other Expenses | CHF 19.83m |
| Earnings | -CHF 60.23m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 12, 2026
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLLC.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 02:47 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molecular Partners AG is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Vosser | J.P. Morgan |
| Wei Chang | Leerink Partners LLC |
| Daina Graybosch | Leerink Partners LLC |